Basilea Pharmaceutica revised revenue guidance for the full year 2023. for the year, the company expects operating result is expected to amount to between CHF 11 million and CHF 15 million versus previously CHF 50 million to CHF 55 million. And the net result is expected at between CHF 2 million and CHF 6 million versus previously CHF 41 million to CHF 46 million.

The company reduced its guidance on total revenue by CHF 3 million.